Search

Johnson and Johnson

Suletud

SektorTervishoid

267.93 0.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

266.23

Max

268.35

Põhinäitajad

By Trading Economics

Sissetulek

299M

5.5B

Müük

1.2B

25B

P/E

Sektori keskmine

31.348

57.366

Aktsiakasum

2.9

Dividenditootlus

1.94

Kasumimarginaal

21.865

Töötajad

138,200

EBITDA

721M

9B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+5.84% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

1.94%

2.16%

Järgmine tulemuste avaldamine

13. okt 2026

Järgmine dividendimakse kuupäev

8. sept 2026

Järgmine aktsia dividendi kuupäev (ex-date)

24. nov 2026

Turustatistika

By TradingEconomics

Turukapital

39B

658B

Eelmine avamishind

267.1

Eelmine sulgemishind

267.93

Uudiste sentiment

By Acuity

27%

73%

54 / 340 Pingereas Healthcare

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. aug 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28. aug 2026, 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27. aug 2026, 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26. aug 2026, 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25. aug 2026, 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24. aug 2026, 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21. aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20. aug 2026, 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

19. aug 2026, 19:32 UTC

News
Social Media

Johnson & Johnson shares advance as EVP Jennifer Taubert exercises options for 15,000 shares valued at $2.38 million and receives regulatory clearance for MONARCH QUEST 3 software.

18. aug 2026, 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

17. aug 2026, 23:06 UTC

Johnson & Johnson's shares are roughly flat in after-market trading. The stock remains positioned above its 20-day moving average and near its one-month range.

14. aug 2026, 19:46 UTC

Johnson & Johnson shares are lower as pharmaceuticals sub-sector weakness persists. The stock reached a session low earlier before recovering slightly.

13. aug 2026, 19:21 UTC

Johnson & Johnson shares are higher, reflecting broader market gains amid stabilizing inflation pressures and a drop in crude oil prices.

12. aug 2026, 23:26 UTC

Johnson & Johnson shares are lower in after-market trading, despite initially rising above Wednesday's close. The stock remains above its 20-day moving average.

11. aug 2026, 19:26 UTC

Johnson & Johnson shares are lower today, influenced by a downturn in the Pharmaceuticals sub-sector. The stock has shown notable volatility during the session.

10. aug 2026, 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

8. aug 2026, 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7. aug 2026, 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6. aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

5. aug 2026, 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

4. aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

3. aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1. aug 2026, 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31. juuli 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

30. juuli 2026, 18:22 UTC

News
Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

29. juuli 2026, 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

28. juuli 2026, 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

27. juuli 2026, 23:31 UTC

News
Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

24. juuli 2026, 23:26 UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

23. juuli 2026, 10:06 UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

5.84% tõus

12 kuu keskmine prognoos

Keskmine 283.69 USD  5.84%

Kõrge 305 USD

Madal 260 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

13

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

54 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat